Internal Medicine, Hematology & Oncology · Houston, TX
NPI
1760701445
Since 2010
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1515 Holcombe Blvd
Houston, TX, 77030
Phone (713) 792-6161
Groups this clinician bills Medicare through
Medicare paid, 2024
$39K
414 services
Medicare patients, 2024
156
Average age 73
Drug cost, 2024
$3.9M
690 prescriptions
Company payments, 2025
$276
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Amishi Y Shah was code 99215 (office e&m - established), 169 times for 76 patients. In total Amishi Y Shah billed 414 services in 18 codes, and Medicare paid $39K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-02-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 169 | 76 | $110.11 | $19K |
| 99214 Office E&M - Established | Facility | 122 | 69 | $71.05 | $8,668 |
| 99233 Hospital E&M - Subsequent | Facility | 21 | 14 | $91.93 | $1,931 |
| 99205 Office E&M - New | Facility | 19 | 19 | $137.28 | $2,608 |
| 99223 Hospital E&M - Initial | Facility | 17 | 17 | $137.91 | $2,344 |
By year: 2022 $51K for 511 services; 2023 $43K for 456 services; 2024 $39K for 414 services.
Medicare prescription drug claims, 2024
In 2024, the drug Amishi Y Shah prescribed most often to Medicare patients was Cabometyx (Cabozantinib S-Malate), with 68 prescriptions and refills. In total Amishi Y Shah wrote 690 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Cabometyx Cabozantinib S-Malate | 68 | 68 | 15 | $1.7M |
| Lenvima Lenvatinib Mesylate | 59 | 59 | 11 | $1.4M |
| Levothyroxine Sodium Generic | 58 | 96 | 20 | $374 |
| Pantoprazole Sodium Generic | 35 | 61 | 17 | $500 |
| Gabapentin Generic | 27 | 29 | Under 11 | $355 |
| Prednisone Generic | 22 | 24 | Under 11 | $40.74 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 22 | 22 | 11 | $332 |
| Ondansetron Odt Ondansetron | 20 | 20 | 11 | $194 |
| Nifedipine Er Nifedipine | 17 | 22 | Under 11 | $127 |
| Dexamethasone Generic | 17 | 17 | 11 | $120 |
| Hydrocortisone Generic | 15 | 15 | Under 11 | $101 |
| Everolimus Generic | 15 | 15 | Under 11 | $39K |
| Furosemide Generic | 15 | 33 | Under 11 | $29.2 |
| Trazodone Hcl Generic | 14 | 14 | Under 11 | $52.7 |
| Inlyta Axitinib | 14 | 14 | Under 11 | $271K |
Brand drugs: - claims; generic drugs: 466 claims; opioid claims: 44.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Amishi Y Shah $276 ($276 in general payments such as food, travel and fees) from 5 companies. The largest payer was Exelixis Inc. with $217.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.